Barclays PLC Has $2.83 Million Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Barclays PLC trimmed its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 35.2% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 331,242 shares of the biopharmaceutical company's stock after selling 180,280 shares during the quarter. Barclays PLC owned 0.21% of Ocular Therapeutix worth $2,830,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Atlas Capital Advisors Inc. acquired a new stake in shares of Ocular Therapeutix during the fourth quarter worth $43,000. AlphaQuest LLC bought a new position in Ocular Therapeutix during the 4th quarter worth about $53,000. Palumbo Wealth Management LLC acquired a new stake in shares of Ocular Therapeutix in the 4th quarter valued at about $100,000. Cibc World Markets Corp bought a new stake in shares of Ocular Therapeutix in the fourth quarter valued at about $124,000. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Ocular Therapeutix during the fourth quarter worth about $149,000. 59.21% of the stock is currently owned by institutional investors and hedge funds.

Ocular Therapeutix Stock Performance

OCUL stock traded down $0.75 during midday trading on Monday, reaching $8.05. 776,124 shares of the company were exchanged, compared to its average volume of 1,434,548. Ocular Therapeutix, Inc. has a one year low of $4.79 and a one year high of $11.78. The firm has a market capitalization of $1.28 billion, a price-to-earnings ratio of -6.02 and a beta of 1.51. The business has a 50-day moving average price of $7.40 and a two-hundred day moving average price of $8.39. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94.

Ocular Therapeutix (NASDAQ:OCUL - Get Free Report) last announced its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The company had revenue of $17.08 million during the quarter, compared to analyst estimates of $16.89 million. Equities research analysts forecast that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

Analysts Set New Price Targets

OCUL has been the topic of a number of recent research reports. Needham & Company LLC reissued a "buy" rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. HC Wainwright reissued a "buy" rating and set a $15.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. Royal Bank of Canada assumed coverage on Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 price target for the company. JMP Securities set a $19.00 price objective on Ocular Therapeutix in a report on Tuesday, March 4th. Finally, William Blair assumed coverage on shares of Ocular Therapeutix in a report on Tuesday, April 8th. They set an "outperform" rating on the stock. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $16.38.

Insider Buying and Selling

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,475 shares of the stock in a transaction on Monday, February 24th. The stock was sold at an average price of $6.87, for a total transaction of $147,533.25. Following the transaction, the insider now owns 3,520,318 shares in the company, valued at $24,184,584.66. This trade represents a 0.61 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Donald Notman sold 11,119 shares of the business's stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total transaction of $86,839.39. Following the completion of the sale, the insider now directly owns 193,444 shares of the company's stock, valued at approximately $1,510,797.64. The trade was a 5.44 % decrease in their position. The disclosure for this sale can be found here. 3.50% of the stock is currently owned by insiders.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.